ROIVANT SCIENCES LTD(NASDAQ:ROIV) stock News

ROIV Latest News, Press Relases and Analysis

All

Press Releases

23 days ago - By: Benzinga

6 Analysts Assess Roivant Sciences: What You Need To Know

24 days ago - By: Stocktwits - Mentions: VFMO PKW GM

Roivant Stock Rises After Drug Achieves Goals In Late-Stage Study: Retail Sees Further Rally To $17

24 days ago - By: The Motley Fool

Why Roivant Sciences Stock Is Soaring Today

24 days ago - By: Benzinga

Roivant/Priovant's Experimental Drug Shows Promise In Rare Skin Disease Trial

24 days ago - By: Investor's Business Daily - Mentions: AAPL

Roivant Leaps Into A Profit-Taking Zone, Stoked By Promise In Autoimmune Disease

24 days ago - By: Roivant Sciences

Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM)

24 days ago - By: Roivant Sciences

Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM)

a month ago - By: Roivant Sciences

Roivant Named on Fortune Media and Great Place To Work’s 2025 Best Workplaces in BioPharma List

a month ago - By: Roivant Sciences

Roivant Named on Fortune Media and Great Place To Work’s 2025 Best Workplaces in BioPharma List

a month ago - By: Pulmovant, Inc.

Pulmovant Receives Orphan Drug Designation in Japan for Mosliciguat for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

a month ago - By: Roivant Sciences

Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

a month ago - By: Roivant Sciences

Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

a month ago - By: Yahoo Finance - Mentions: IMVT

Roivant Sciences (ROIV) Announces Q1 2025 Business Update

2 months ago - By: Yahoo Finance

Why Roivant Sciences Stock Bounced Back on Tuesday

2 months ago - By: The Motley Fool

Why Roivant Sciences Stock Bounced Back on Tuesday

2 months ago - By: Yahoo Finance

Why Roivant Sciences Stock Was Slipping on Monday

2 months ago - By: Yahoo Finance - Mentions: ABX UBS TSLA EA ...

Stock Market Today: S&P 500 upgraded by Citi, UBS

2 months ago - By: Zacks Investment Research - Mentions: FENC

Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates

2 months ago - By: Roivant Sciences

Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update

2 months ago - By: Roivant Sciences

Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update

2 months ago - By: Zacks Investment Research - Mentions: KURA

Kura Oncology (KURA) Reports Q2 Loss, Lags Revenue Estimates

2 months ago - By: Zacks Investment Research - Mentions: RYTM

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates

2 months ago - By: Roivant Sciences

Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025

2 months ago - By: Roivant Sciences

Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025

4 months ago - By: Pulmovant, Inc.

Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics

4 months ago - By: Roivant Sciences

ROIVANT SCIENCES LTD (ROIV) Stock News

ROIV Latest News, Press Relases and Analysis

6 Analysts Assess Roivant Sciences: What You Need To Know

Roivant Stock Rises After Drug Achieves Goals In Late-Stage Study: Retail Sees Further Rally To $17

Why Roivant Sciences Stock Is Soaring Today

Roivant/Priovant's Experimental Drug Shows Promise In Rare Skin Disease Trial

Roivant Leaps Into A Profit-Taking Zone, Stoked By Promise In Autoimmune Disease

Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM)

Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM)

Roivant Named on Fortune Media and Great Place To Work’s 2025 Best Workplaces in BioPharma List

Roivant Named on Fortune Media and Great Place To Work’s 2025 Best Workplaces in BioPharma List

Pulmovant Receives Orphan Drug Designation in Japan for Mosliciguat for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

Roivant Sciences (ROIV) Announces Q1 2025 Business Update

Why Roivant Sciences Stock Bounced Back on Tuesday

Why Roivant Sciences Stock Bounced Back on Tuesday

Why Roivant Sciences Stock Was Slipping on Monday

Stock Market Today: S&P 500 upgraded by Citi, UBS

Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates

Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update

Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update

Kura Oncology (KURA) Reports Q2 Loss, Lags Revenue Estimates

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates

Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025

Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025

Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics

Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis